Latest Pharmacovigilance Podcast Episodes
#30 Preventing and reporting medication errors – Rabat CC & UMC
Drug Safety Matters - May 15, 2024 11:00 - 33 minutesLook-alike medicines, unclear communication and distractions during administration – medication errors may occur for many different reasons. They all have in common that they are unintended mistakes in the drug treatment process that may or may not lead to patient harm. In this episode Ghita Ben...
#29 When medicines change our behaviour – Michele Fusaroli
Drug Safety Matters - April 23, 2024 09:00 - 30 minutesMedicines can affect our personality in positive ways, but they may also lead to destructive behaviours that can damage our relationships, finances, and overall quality of life. Michele Fusaroli from the University of Bologna explains how to diagnose and treat drug-induced impulse control disord...
#28 Catching black swans – François Montastruc
Drug Safety Matters - February 29, 2024 08:00 - 27 minutesSerious and unexpected adverse drug reactions – the ‘black swans’ of pharmacovigilance – can place enormous strain on safety monitoring systems. Drawing examples from the COVID-19 pandemic, François Montastruc from Toulouse University Hospital explains how we can get better at dealing with the u...
#27 When drugs damage the liver – Rita Baião
Drug Safety Matters - February 01, 2024 09:00 - 28 minutesThe liver is the primary site for drug metabolism in the body, but it can be severely damaged by medicines or their toxic compounds. Rita Baião from the North Lisbon University Hospital Center reviews what pharmacovigilance professionals should know about drug-induced liver injury (DILI). Tune ...
#26 What's trending in pharmacovigilance? – Angela Caro
Drug Safety Matters - December 20, 2023 08:00 - 28 minutesWhat did the drug safety community achieve in 2023 and how will the field develop in 2024? As the year comes to a close, we asked Angela Caro, president of the International Society of Pharmacovigilance (ISoP), to walk us through current and future trends in pharmacovigilance. Tune in to find o...
#25 A week in the name of medicines safety – part 2
Drug Safety Matters - November 13, 2023 10:00 - 33 minutesTo mark #MedSafetyWeek, which took place from 6–12 November, we’re releasing a special two-part episode on pharmacovigilance communication campaigns. In this second part, we hear from three #MedSafetyWeek veterans – Anne-Cécile Vuillemin from the Ministry of Health in Luxembourg, Ban Al-Shimran ...
#24 A week in the name of medicines safety – part 1
Drug Safety Matters - November 02, 2023 13:00 - 27 minutesTo mark #MedSafetyWeek, which takes place from 6–12 November, we’re releasing a special two-part episode on pharmacovigilance communication campaigns. In this first part, we speak to Mitul Jadeja from the Medicines and Healthcare products Regulatory Agency in the UK about under-reporting and how...
Uppsala Reports Long Reads – The colour of signals
Drug Safety Matters - September 29, 2023 14:00 - 33 minutesHerbal remedies have been used for thousands of years to treat what ails us. Yet why do we still know so little about their potential side effects compared to modern medicines? This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance ...
Uppsala Reports Long Reads – Empowering patients as partners
Drug Safety Matters - September 05, 2023 12:00 - 42 minutesA patient's perspective can ensure safe medical care and lead to new insights that traditional research may overlook. But how do we best harness that perspective to improve patient outcomes? This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s phar...
#23 Assessing safety in clinical trials – Marianne Lunzer & Sanja Prpić
Drug Safety Matters - June 27, 2023 14:00 - 31 minutesMedicines safety monitoring is a continuous process that begins with pre-marketing clinical trials and continues with post-marketing studies to fill any gaps in knowledge. With Marianne Lunzer from AGES and Sanja Prpić from HALMED, we review the pros and cons of various study types and the impor...
#22 Reforming pharmacovigilance education – Michael Reumerman
Drug Safety Matters - May 08, 2023 12:00 - 32 minutesHealthcare professionals are key players in medicines safety but they often lack the time or knowledge to report adverse drug reactions. To change that, we need to urgently rethink how we teach pharmacovigilance, argues Michael Reumerman from Amsterdam University Medical Centers. Tune in to fin...
#21 Unlocking the power of real-world data – Patrick Ryan
Drug Safety Matters - March 30, 2023 09:00 - 33 minutesThe vast amount of real-world data collected during routine clinical care is a treasure trove of safety information – but there are challenges to overcome before this rich source of evidence can be applied to pharmacovigilance. Patrick Ryan from Johnson & Johnson discusses how to harness real-wo...
#20 The evidence for signals – Daniele Sartori
Drug Safety Matters - February 23, 2023 08:00 - 45 minutesSpontaneous reports of adverse drug reactions are a common source of evidence in pharmacovigilance, but as the science evolves, so do the types of data used to find and assess signals. Uppsala Monitoring Centre’s Daniele Sartori reviews how signal detection practices have changed over time. Tun...
Uppsala Reports Long Reads – Unmasking data in the COVID-19 vaccine era
Drug Safety Matters - January 26, 2023 12:00 - 21 minutesMost pharmacovigilance professionals will have heard of masking – a statistical issue where reports for one drug hide signals for other drugs. But the problem gained fresh attention when record amounts of reports began piling up for the COVID-19 vaccines. How should we be unmasking data in the C...
#19 Lessons in pandemic pharmacovigilance – Elena Rocca
Drug Safety Matters - December 15, 2022 08:00 - 33 minutesThe COVID-19 pandemic forced pharmacovigilance experts to revisit their processes to deal with unprecedented volumes of data and catch unexpected safety issues. Elena Rocca from Oslo Metropolitan University reviews the challenges of a global healthcare emergency – and what it can teach us about ...
#18 The IDMP standards explained – Malin Fladvad & Olle Lagerlund
Drug Safety Matters - September 29, 2022 08:00 - 23 minutesThe Identification of Medicinal Products (IDMP) standards promise to harmonise how pharmaceutical products and substances are described around the world. But how will that benefit patients and who will make sure the standards are properly implemented? Uppsala Monitoring Centre’s Malin Fladvad an...
#17 Why we need vaccine surveillance systems – Madhava Balakrishnan
Drug Safety Matters - August 24, 2022 12:00 - 27 minutesPublic trust in vaccines hinges on their safety – but to make sure vaccines are safe, we must have systems in place to detect and manage any side effects. Dr Madhava Ram Balakrishnan, medical officer for vaccine safety at the World Health Organization, discusses how to build an effective vaccine...
#16 How drug safety can help fight resistant bugs – Jean Marie Vianney Habarugira & Albert Figueras
Drug Safety Matters - June 30, 2022 07:00 - 33 minutesManaging antimicrobial resistance (AMR) will require innovative solutions from many different disciplines. Could pharmacovigilance be one of them? Jean Marie Vianney Habarugira and Albert Figueras, who have been investigating how drug safety tools could help track AMR, think it’s time the two co...
#15 Safety of HIV medications – Henry Zakumumpa
Drug Safety Matters - April 29, 2022 13:00 - 33 minutesWith the right care, people infected with HIV can lead long and healthy lives. But as with any life-long medical treatment, it is important to acknowledge and manage any side effects. Henry Zakumumpa from Makerere University School of Public Health tells us about the potential harms of new HIV t...
#14 Advancing pharmacovigilance in Africa – Eleni Aklillu & Abbie Barry
Drug Safety Matters - March 24, 2022 08:00 - 37 minutesAccess to medical products has increased considerably in Africa in recent years, but safety monitoring systems haven’t exactly kept pace and many African countries still struggle to address safety issues. We sat down with Eleni Aklillu and Abbie Barry of the PROFORMA project to learn about their...
#13 How to talk about risks – Alexandra Freeman
Drug Safety Matters - February 24, 2022 08:00 - 38 minutesPeople’s perception of risk can vary greatly from person to person, making it challenging for healthcare professionals to communicate benefits and harms of medicines in a balanced fashion. Alexandra Freeman from the Winton Centre for Risk and Evidence Communication discusses how to give patients...
Uppsala Reports Long Reads – Safety issues faced by refugee communities
Drug Safety Matters - January 27, 2022 10:00 - 25 minutesThe loss of vital health records is a universal problem for refugees. When their medical information goes missing, patients are less likely to receive the care they need and more likely to be prescribed the wrong treatments. Thankfully, the International Society of Pharmacovigilance Egypt Chapte...
#12 Improving signal detection with vigiGroup – Jim Barrett & Joe Mitchell
Drug Safety Matters - December 16, 2021 15:00 - 23 minutesStatistical tools can not only cut through the noise in large pharmacovigilance databases. They can also help identify more clinically meaningful patterns in the data. Uppsala Monitoring Centre’s Jim Barrett and Joe Mitchell explain how vigiGroup, a novel clustering algorithm, can bring value to...
#11 Talking about vaccine safety – Anthony Cox & Daniel Salmon
Drug Safety Matters - November 03, 2021 12:00 - 28 minutesWith vaccine hesitancy on the rise and misinformation spreading like wildfire on social media, drug safety specialists may have a hard time knowing how to talk about side effects without affecting people’s trust in vaccinations. Anthony Cox from the University of Birmingham and Daniel Salmon fro...
Uppsala Reports Long Reads – The KIDs List
Drug Safety Matters - October 05, 2021 14:00 - 31 minutesIt’s not always easy to choose the best medicine for a child. Some drugs are inappropriate for young patients, while others require special consideration or monitoring. For years, clinicians had only historical dogmas, word of mouth and their own experience to guide their choices. But a valuable...
Uppsala Reports Long Reads – Convincing the vaccine hesitant
Drug Safety Matters - August 30, 2021 11:00 - 34 minutesFuelled by disinformation and an array of other cultural and economic factors, vaccine hesitancy is one of the greatest global health communication challenges of our times. But to craft the empathetic and tailored communication strategies required to boost confidence in vaccines, we first need t...
#10 Tailoring drug therapy to your genes – Qun-Ying Yue
Drug Safety Matters - July 29, 2021 07:00 - 29 minutesGenetic variation is one of the reasons people differ in their response to medicines. Understanding that variation can inform more refined choices of drugs and doses – ultimately preventing undesired side effects. Join us as we discuss past, present and future of pharmacogenomics with Uppsala Mo...
#10 – Tailoring drug therapy to your genes – Qun-Ying Yue
Drug Safety Matters - July 29, 2021 07:00 - 29 minutesGenetic variation is one of the reasons people differ in their response to medicines. Understanding that variation can inform more refined choices of drugs and doses – ultimately preventing undesired side effects. Join us as we discuss past, present and future of pharmacogenomics with Uppsala Mo...
#9 Keeping vaccines safe – Helena Sköld & Annette Rudolph
Drug Safety Matters - June 24, 2021 07:00 - 26 minutesWith COVID-19 vaccinations rolling at full speed in many countries, there’s a lot of talk about vaccine safety monitoring. But what exactly does that mean and how should we be interpreting data on side effects? Uppsala Monitoring Centre’s Helena Sköld and Annette Rudolph walk us through the basi...
Uppsala Reports Long Reads – Substandard and falsified COVID-19 vaccines in the Americas
Drug Safety Matters - May 27, 2021 06:00 - 21 minutesWhile COVID-19 vaccinations are picking up speed in many wealthy countries, citizens of lower-income countries still face a long wait – and where demand exceeds supply, black markets tend to form. So to curb the spread of substandard and falsified products, says drug regulatory specialist Danin...
Related Pharmacovigilance Topics